The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the importance of utilizing measurable residual disease (MRD) in transplant-ineligible patients with multiple myeloma (MM). MRD can be useful in this patient population to measure the depth and duration of treatment responses and to limit the duration of therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Janssen, Binding Site, Millenium, BMS (Celgene), Sanofi, Regeneron, Pharmacyclics, Pfizer, Merck, Kite, Juno, Bayer, Aztrazeneca, AMGEN, Adaptive Biotechnologies, AbbVie
Membership on Board of Directors/Advisory Committee: AZBio, Antegene, Oncotracker, Caris Life Sciences, Adaptive Biotechnologies
Patents & Royalties: FISH
